Reducing Drug Allergies Without Alerting the Immune System

by Bidita Debnath on  December 4, 2014 at 11:25 PM Research News   - G J E 4
An enzyme that usually triggers strong allergic reactions now circulates in the veins without alerting the immune system in a group of mice.
 Reducing Drug Allergies Without Alerting the Immune System
Reducing Drug Allergies Without Alerting the Immune System

As INRS Énergie Matériaux Télécommunications Research Centre Professor Marc A. Gauthier explains in an article published in the journal Nature Communications, a polymer was used to camouflage the enzyme before it was injected into the rodents.

This was achieved by coating the enzyme to avoid an immune response in a manner that does not compromise its activity. The first in vivo demonstration has opened the door to numerous clinical applications.

The strategy proposed by Professor Gauthier and his Swiss co-investigators solves a very real problem. Molecules with high therapeutic potential sometimes degrade rapidly in the bloodstream or cause allergies. This is the case for an enzyme used to fight lymphoblastic leukemia, L-asparaginase, that causes allergies in nearly 20% of patients.

The research team used a comb-shaped polymer (poly-OEGMA*) that covers the enzyme like a fur coat. Antibodies are unable to attach to the protected enzyme: L-asparaginase combined with poly-OEGMA is 3,000 times less recognizable by antibodies than "naked" L-asparaginase.

"Generally speaking, when other cutting-edge approaches in the field are used, enzymes are efficiently protected but lose a significant amount of their activity," said Gauthier. "We are the first to show, in vivo, that comb-shaped polymers are much better at protecting enzymes than other approaches, since they reduce enzyme activity only slightly."

For the approach to work, the molecules that the enzyme transforms must be small enough to slide between the polymer hairs. Otherwise, the reaction cannot take place. In the case of L-asparaginase, the efficacy of the approach is now proven and it can be tested on other similar enzymes.

Furthermore, poly-OEGMA could protect other therapeutic molecules that are rapidly degraded, by preventing them from making contact with the proteins that inactivate or break them. This other application is equally promising.

Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All